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During the past decade, there has been an expand-
ing research activity in the largely neglected problem
of urolithiasis, and considerable progress has been
made concerning physicochemical and physiological
basis for stone formation, development of improved
diagnostic criteria, and formulation of new regimens
for treatment. This involvement has been a multi-
disciplinary effort involving basic as well as clinical
scientists. Notwithstanding the strides made, uroli-
thiasis research is still at an infancy stage. Considera-
ble controversy and misconception remain, a situa-
tion which probably reflects the limited current
understanding of stone formation and prevention.
This symposium represents a review of different
aspects of urolithiasis research which has been car-
ried out by leading investigators representing various
disciplines. The contributors' efforts comprise a
broad discussion of current status of urolithiasis re-
search, with inclusion of different points of view. It is
recognized, however, that the authors' own experi-
ences and research endeavors may have influenced
their contribution. Thus, some of the conclusions
stated may not represent the prevailing view, even
among the contributors themselves.
In the next article of this issue, Dr. Finlayson
reviews physicochemical principles of stone forma-
tion. He provides an in-depth discussion of concepts
of nucleation (formation of nucleus or crystal nidus),
crystal growth, and aggregation. He emphasizes cer-
tain deviations from these principles when they are
applied to the study of complex solutions such as
urine. For example, the urinary saturation with re-
spect to the stone-forming constituents sometimes
may not be estimated reliably because of the diffi-
culty in the accurate determination of ionic activities.
Dr. Finlayson concludes that the crystal nidus does
not form in urine de novo by homogeneous nuclea-
tion, but probably proceeds by nonhomogeneous or
heterogeneous nucleation, since urine invariably
contains particle impurities. He questions, however,
the biological relevance of some forms of heteroge-
neous nucleation, such as calcium oxalate crystalli-
zation by monosodium urate, because the rate of
growth is probably insufficient to cause occlusion or
to stabilize the mass in the urinary tract.
Next, Dr. Fleisch presents evidence that urine
contains inhibitors which retard and promoters
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which facilitate the nucleation and growth of crystal
nidus. Promoters may include either colloidal or
crystalline phases (e.g., monosodium urate) and or-
ganic matrix. The action of these substances may be
localized to a specific step in the crystallization pro-
cess, or it may be more generalized, involving sev-
eral or all stages. The relative activity of these sub-
stances depends on the particular crystallization
process examined and the method utilized. The bio-
logical importance of these observations was shown
by the demonstration that the urinary environment
from certain patients with stones may have a defi-
ciency or reduced activity of inhibitors and/or an
increased activity of promoters. He concurs with Dr.
Finlayson regarding the inadequacies of some of the
current methodologies for the assessment of inhibi-
tors or promoter activity, and he warns against tech-
niques for crystal growth or aggregation utilizing
diluted urine.
Dr. Griffith presents a broad discussion of patho-
genesis and management of struvite stones. The key
to stone formation appears to be an infection of the
urinary tract with urea-splitting organisms. Thus,
consequent to increases in urinary pH and ammo-
nium content, the urinary environment becomes su-
persaturated with respect to struvite. The control of
urinary tract infection with appropriate antibiotic
therapy or treatment with a urease inhibitor has been
shown to reduce urinary saturation of struvite.
Moreover, there is some evidence, albeit prelimi-
nary, that these treatments may inhibit new stone
formation or sometimes cause dissolution of existing
stones. The groundwork, therefore, has been laid for
the delineation of physicochemical basis for struvite
stone formation and for the definition of rationale for
therapy.
The renal stones containing calcium may be cate-
gorized on the basis of whether they are associated
with disordered metabolism of calcium (Smith;
Thomas; Yendt and Cohanim; this issue), oxalate
(Williams, this issue), or uric acid (Coe, this issue).
The physicochemical basis for stone formation and
physiological derangements leading to these abnor-
mal renal excretions are partly understood. Hyper-
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calciuria and hyperoxaluria are both recognized as
major determinants for the supersaturation with re-
spect to calcium salts. Hyperuricosuria may cause
formation of calcium stones by producing urinary
supersaturation with respect to monosodium urate,
and by promoting either heterogeneous nucleation or
crystal aggregation of calcium oxalate (Dr. Coe's
article).
Concerning physiological derangements, Dr.
Smith indicates that the most prevalent form of cal-
cium urolithiasis is "idiopathic renal lithiasis." This
term describes stone formation in which known
causes (such as renal tubular acidosis, hyperoxalu-
na, hypercalcemia, and urinary tract infection with
urea-splitting organisms) have been excluded. When
this condition is associated with hypercalciuria, as is
often the case, it previously has been termed "idio-
pathic hypercalciuria." The improved understanding
of pathogenetic mechanisms and delineation of un-
derlying "metabolic" derangements undoubtedly
will require subclassification of the idiopathic group.
For example, idiopathic hypercalciuria should no
longer be regarded as a homogeneous entity. Despite
prevailing controversy, two major subtypes of
hypercalciunia are recognized: absorptive hypercal-
ciuria of enhanced intestinal calcium absorption and
renal hypercalciuria of an impaired renal tubular
reabsorption of calcium. The exact mechanism for
the high intestinal calcium absorption has not been
clarified fully.
The physiologic basis for hyperoxaluria and hyper-
uricosuria associated with calcium oxalate uroli-
thiasis has been investigated also. Dr. Williams dis-
cusses causes for hyperoxalunia. The most common
cause for the high oxalate excretion is recognized to
be the excessive intestinal absorption of oxalate in
ileal disease or resection (entenic hyperoxaluria). Dr.
Coe shows that hyperuricosuria results usually from
an overindulgence in purine-rich foods and some-
times from an overproduction of uric acid (hyperuri-
cosuric calcium oxalate urolithiasis).
The improved understanding of physicochemical
and physiological basis for calcium stone formation
allows for selection of specific treatment measures
which are designed to correct those defects, as is
being done for struvite stones. The treatment of
calcium stones associated with enteric hyperoxaluria
or hyperuricosuria has been directed at reducing the
renal excretion of oxalate or uric acid, respectively.
Dr. Williams provides some evidence that a high
calcium intake or a substitution of dietary fat by
medium-chain fatty acids may inhibit oxalate absorp-
tion, lower urinary oxalate, and reduce the super-
saturation with respect to calcium oxalate. If con-
firmed, it may provide the ground work for the
rational therapy for enteric hyperoxaluria. Dr. Coe
suggests that the reduction of urinary uric acid by
allopurinol may reduce significantly the incidence of
new calcium stone formation in patients with hyper-
unicosunia. Unfortunately, the exact physicochemi-
cal mechanisms have not been clarified.
The management of calcium stones associated
with hypercalciuria has also been directed at restor-
ing normal urinary chemical composition. Several
drugs have been employed for the correction of
hypercalciuria, including sodium cellulose phos-
phate, orthophosphate (Dr. Thomas's article), and
thiazide (Dr. Yendt's article). Sodium cellulose
phosphate specifically inhibits intestinal calcium ab-
sorption. When appropriately used, it may provide
the optimum treatment for absorptive hypercalci-
uria, since it has been shown to correct the hypercal-
ciuria, reduce the urinary supersaturation of calcium
phosphate and calcium oxalate, and retard stone
formation. Thus, the indications for urease inhibitor,
oral calcium, allopuninol, and sodium cellulose phos-
phate seem reasonably well established when re-
stricted to the treatment of struvite stones, enteric
hyperoxalunia, hyperuricosuric calcium oxalate
nephrolithiasis, and absorptive hypercalciuria,
respectively.
Dr. Thomas and Drs. Yendt and Cohanim, how-
ever, indicate that the use of orthophosphate and
thiazide may be more broad. Orthophosphate and
thiazide probably augment urinary inhibitor activity
besides restore normal urinary calcium. Thus, they
may retard nucleation and growth of nidus as well as
reduce the saturation of calcium oxalate. For this
reason, Dr. Thomas and Drs. Yendt and Cohanim
suggest that these drugs may be clinically useful even
in calcium urolithiasis associated with normocalci-
uria. Moreover, Dr. Thomas provides evidence that
orthophosphate may be useful in mild primary hyper-
parathyroidism, medullary sponge kidney, and idio-
pathic hypercalciuria (renal and absorptive hypercal-
ciurias). Drs. Yendt and Cohanim suggest that
thiazide may be effective in the control of stone
formation in renal and absorptive hypercalciunias
and medullary sponge disease. The broad usage of
these drugs is seemingly inconsistent with the goals
of other regimens, particularly those of urease inhibi-
tors and sodium cellulose phosphate, which are di-
rected at the correction of both physicochemical and
physiological derangements, as was espoused by Dr.
Fleisch. It would seem more logical, for example,
that the use of thiazide should be restricted to renal
hypercalciuria, since this drug has been shown to
correct the "renal leak" of calcium, secondary
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hyperparathyroidism, and intestinal hyperabsorp-
tion of calcium. It is recognized, however, that
the full physiological action of orthophosphate and
thiazide is not known. The possibility that they
may eventually restore normal calcium absorption
in absorptive hypercalciuria cannot be excluded
(Yendt and Cohanim, this issue).
This symposium emphasizes that despite recent
advances, current understanding of stone formation
and prevention is still very limited. The prevailing
disagreements regarding pathogenetic mechanisms
and indications for therapy probably reflect this re-
stricted knowledge. Further progress undoubtedly
will provide a better consensus and will lead to a
formulation of a more rational basis of therapy. It is
hoped that this symposium will contribute to the
background against which future advances in uro-
lithiasis research must be critically assessed.
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